Nutraceuticals in the management of patients with statin‐associated muscle symptoms, with a note on real‐world experience. Issue 1 (24th January 2018)

• Record Type: Journal Article
• Authors: Ward, Natalie C.; Pang, Jing; Ryan, Jacqueline D.M.; Watts, Gerald F.
• Is Part Of: Clinical cardiology. Volume 41:Issue 1(2018)
• Page Start: 159
• Page End: 165
• Publication Date: 2018-01-24
• Subjects: Low‐Density Lipoprotein Cholesterol -- Nutraceuticals -- SAMS -- Statin Myopathy; Cardiology -- Periodicals; 616.12005
• DOI: 10.1002/clc.22862
• Languages: English
• ISSNs: 0160-9289

Abstract

Abstract : There is considerable evidence for the role of low‐density lipoprotein cholesterol (LDL‐C) in the development of atherosclerotic cardiovascular disease. Although statin therapy remains the most frequency prescribed medication to reduce LDL‐C and lower risk of cardiovascular disease, a considerable number of patients develop muscle‐related side affects. This review summarizes recent literature supporting the role of nutraceuticals as LDL‐C–lowering therapy in statin‐intolerant patients, with evidence from our own clinical practices.